Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORPEDO: SBRT for Inoperable Pancreatic Adenocarcinoma
NCT06691425Recruiting
- Sponsor
- Center for Oncological Research
- Start
- Jul 2024
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Center for Oncological Research. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2024; status: recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06691425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691425.